3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel  blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z's cutting-edge high-throughput drug discovery platform and introduce new avenues for non-stimulant-based ADHD treatment.

ADHD is a prevalent neurodevelopmental disorder with limited treatment options. Current stimulant medications, such as methylphenidate, offer benefits to some but are often associated with side effects, abuse potential, and a high non-response rate. 3Z Pharmaceuticals is committed to addressing these gaps by pioneering alternative, non-stimulant therapeutics.

Dr. Karl Karlsson a neuroscientist, CEO of 3Z Pharmaceuticals and Professor of Biomedical Engineering at Reykjavik University, commented on the study's impact, "This research represents a paradigm shift in ADHD therapeutics. Our findings not only validate the mechanism impacted by amlodipine as a promising candidate for non-stimulant ADHD treatment but also underscore the power of our high-throughput screening and genetic modeling approaches, performed in close alliance with biotx.ai. This is an exciting step forward in our mission to deliver more effective and well-tolerated treatments for ADHD."

Building on these findings, 3Z Pharmaceuticals is advancing a variant of the therapeutic towards clinical development, leveraging its established safety profile and precise mechanism of action to introduce transformative ADHD therapy.